恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析*

doi:10.3969/j.issn.1672-5069.2023.02.008

摘要/Abstract

摘要： 目的评价抗病毒治疗慢性乙型肝炎(CHB)合并非酒精性脂肪性肝病(NAFLD)患者的疗效。方法 2016年1月～2020年6月我院收治的CHB合并NAFLD患者125例和同期CHB患者120例,均接受恩替卡韦治疗48 w。使用FibroScan 502型肝脏弹性成像仪检测肝脏受控衰减参数(CAP)。常规检测血清HBeAg和HBV DNA。采用COX比例风险回归模型分析影响疗效的因素。结果在基线资料方面,本研究纳入的CHB合并NAFLD组血小板(PLT)计数、丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、甘油三酯(TG)、总胆固醇(TC)、LDL和CAP分别为189.0(156.0,212.0)×10⁹/L、78.0(40.0,138.0)U/L、72.0(26.0,98.0)U/L、4.4(3.0,5.8)mmol/L、 5.9(4.9,7.3)mmol/L、3.8(2.7,4.5)mmol/L和290.0(245.0,315.0)dB/m,显著不同于CHB组[分别为154.0(127.0,184.0)×10⁹/L、198.0(43.0,160.0)U/L、121.0(29.0,105.0)U/L、1.7(1.2,3.2)mmol/L、4.9(4.4,5.4)mmol/L、2.9(2.5,3.6)mmol/L和194.0(170.0,232.0)dB/m,P<0.05]; 在治疗24 w和48 w末,两组血清HBV DNA均大部或全部转阴(P>0.05),血清HBeAg阴转率都很低(P>0.05),但CHB合并NAFLD组血清ALT复常率则分别为44.8%和66.4%,显著低于CHB组的95.8%和100.0%(P<0.05);经多因素 COX比例风险回归模型分析显示,CAP值是影响ALT复常的独立危险因素(HR:0.996,95%CI:0.994～0.999,P<0.05),即CAP值较高的患者血清ALT复常率较低。结论合并NAFLD将影响接受恩替卡韦治疗的CHB患者血生化学应答,因此在抗病毒治疗的同时还需要针对性地处理肝脂肪变。

关键词: 慢性乙型肝炎, 非酒精性脂肪性肝病, 恩替卡韦, 受控衰减参数, 治疗

Abstract: Objective The aim of this study was to investigate the impact of nonalcoholic fatty liver diseases (NAFLD) on antiviral response to entecavir in patients with chronic hepatitis B (CHB). Methods 125 patients with CHB and concomitant NAFLD and 120 patients with CHB at the same time were recruited in our hospital between January 2016 and June 2020, and all received entecavir therapy for 48 weeks. The controlled attenuation parameter (CAP) of the liver was determined by FibroScan 502, and serum HBV DNA and HBeAg were detected routinely. The COX proportional risk regression model was applied to multivariate correlation analysis. Results The blood platelet (PLT) counts, alanine aminotransferase (ALT), aspartate aminotransferase (AST), triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL) and CAP in patients with CHB and NAFLD were 189.0(156.0,212.0)×10⁹/L, 78.0(40.0, 138.0)U/L, 72.0(26.0, 98.0)U/L, 4.4(3.0, 5.8)mmol/L, 5.9(4.9,7.3)mmol/L, 3.8(2.7, 4.5)mmol/L and 290.0(245.0, 315.0)dB/m, all significantly different compared to [154.0(127.0, 184.0)×10⁹/L, 198.0(43.0, 160.0)U/L, 121.0(29.0, 105.0)U/L, 1.7(1.2, 3.2)mmol/L, 4.9(4.4, 5.4)mmol/L, 2.9(2.5, 3.6)mmol/L and 194.0(170.0, 232.0)dB/m, respectively, P<0.05] in patients with CHB; at the end of 24 week and 48 week treatment, almost all patients in the two groups had their serum HBV DNA transferred to negative and few patients in the two groups had their serum HBeAg transferred to negative (P>0.05), but serum ALT normalization rates in patients with CHB and NAFLD were 44.8% and 66.4%, both significantly lower than 95.8% and 100.0%(P<0.05) in patients with CHB; the multivariate COX analysis showed that the CAP was the independent risk factor for serum ALT normalization (HR:0.996, 95%CI:0.994-0.999, P<0.05), suggesting that the more high the CAP, the more lower the ALT normalization rates. Conclusion The concomitant NAFLD might frustrate the biochemical response to entecavir antiviral therapy in patients with CHB, which warrants simultaneously appropriate management of hepatic steatosis.

Key words: Hepatitis B, Nonalcoholic fatty liver diseaseS, Controlled attenuation parameter, Entecavir, Therapy

魏丽, 刘博, 赵楠, 梁丽君. 恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 181-184.

Wei Li, Liu Bo, Zhao Nan, et al.. Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B?[J]. Journal of Practical Hepatology, 2023, 26(2): 181-184.

参考文献

[1] Martin P, Nguyen MH, Dieterich DT, etal. Treatment algorithm for managing chronic hepatitis B virus infection in the United States: 2021 Update. Clin Gastroenterol Hepatol, 2022, 20(8): 1766-1775.
[2] Li ZB, Li L, Niu XX, et al. Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia. Liver Int, 2021, 41(6): 1254-1264.
[3] García-López M, Lens S, Pallett LJ, et al. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J Hepatol, 2021, 74(5): 1064-1074.
[4] Lok AS, Zoulim F, Dusheiko G, et al. Durability of hepatitis B surface antigen loss with nucleotide analogue and peginterferon therapy in patients with chronic hepatitis B. Hepatol Commun, 2019, 4(1): 8-20.
[5] Fung J, Seto WK, Lai CL, et al. Extrahepatic effects of nucleoside and nucleotide analogues in chronic hepatitis B treatment. J Gastroenterol Hepatol, 2014, 29(3): 428-434.
[6] Makri E, Goulas A, Polyzos SA. Epidemiology, pathogenesis, diagnosis and emerging treatment of nonalcoholic fatty liver disease. Arch Med Res, 2021, 52(1): 25-37.
[7] Dougherty JA, Guirguis E, Thornby KA. A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother, 2021, 55(1): 65-79.
[8] Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology, 2019, 156(6): 1717-1730.
[9] Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol, 2017, 66(5): 1022-1030.
[10] Piccinni R, Rodrigues SG, Montani M, et al. Controlled attenuation parameter reflects steatosis in compensated advanced chronic liver disease. Liver Int, 2020, 40(5): 1151-1158.
[11] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版). 中华肝脏病杂志, 2011, 19(1): 13-24.
[12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年修订版). 中华肝脏病杂志, 2010, 18(3): 163-166.
[13] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2019年版). 临床肝胆病杂志, 2019, 35(12): 2648-2669.
[14] Li J, Le AK, Chaung KT, et al. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int, 2020, 40(5): 1052-1061.
[15] Kim NH, Cho YK, Kim BI, et al. Effect of metabolic syndrome on the clinical outcomes of chronic hepatitis B patients with nucleos(t)ide analogues treatment. Dig Dis Sci, 2018, 63(10): 2792-2799.
[16] Zhu LY, Wang YG, Wei LQ, et al. The effects of the insulin resistance index on the virologic response to entecavir in patients with HBeAg-positive chronic hepatitis B and nonalcoholic fatty liver disease. Drug Des Devel Ther, 2016, 10: 2739-2744.
[17] Rastogi A, Sakhuja P, Kumar A, et al. Steatosis in chronic hepatitis B: prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol, 2011, 54(3): 454-459.
[18] Zhang Z, Pan Q, Duan XY, et al. Fatty liver reduces hepatitis B virus replication in a genotype B hepatitis B virus transgenic mice model. J Gastroenterol Hepatol, 2012, 27(12): 1858-1864.
[19] Chen YC, Jeng WJ, Hsu CW, et al. Impact of hepatic steatosis on treatment response in nuclesos(t)ide analogue-treated HBeAg-positive chronic hepatitis B: a retrospective study. BMC Gastroenterol, 2020, 20(1): 146.
[20] Feldstein AE, Canbay A, Angulo P, et al. Hepatocyte apoptosis andFAS expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology, 2003, 125(2): 437-443.
[21] Miyake T, Akbar SM, Yoshida O, et al. Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease. J Gastroenterol, 2010, 45(8): 859-867.
[22] 宓余强, 刘勇钢, 徐亮, 等. 慢性乙型肝炎患者肝脂肪变与肝脏HBsAg和HBcAg的关系. 中华消化杂志, 2012, 32(5): 316-319.
[23] Kim NH, Cho YK, Kim BI, et al. Effect of metabolic syndrome on the clinical outcomes of chronic hepatitis B patients with nucleos(t)ide analogues treatment. Dig Dis Sci, 2018, 63(10): 2792-2799.
[24] Ceylan B, Arslan F, Batirel A, et al. Impact of fatty liver on hepatitis B virus replication and virologic response to tenofovir and entecavir. Turk J Gastroenterol, 2016, 27(1): 42-46.

恩替卡韦抗病毒治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者病毒学应答情况分析^*

Would the coincidence of nonalcoholic fatty liver diseases impact the antiviral response to enticavir therapy in patients with chronic hepatitis B?

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	邓玉婷, 周俊英. 布加综合征诊治研究进展[J]. 实用肝脏病杂志, 2023, 26(2): 156-159.
[2]	尹雯, 鲁科翔, 王雪, 王彩艳. 恩替卡韦联合苦参素治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 173-176.
[3]	范明芳, 田瑛, 周倩, 接贵涛, 刘淑芳. 慢性丙型肝炎合并非酒精性脂肪性肝病患者血清RBP4和SREBP-1c水平变化分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 185-188.
[4]	郝蕾, 高卫东, 胡娟娟, 张琳, 邢亚恒. 非酒精性脂肪性肝病患者血清脂联素、维生素D和载脂蛋白B水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 189-192.
[5]	方颖, 金家东, 汪芾, 周达. 新冠疫情期间情绪对非酒精性脂肪性肝病患者血生化指标的影响^*[J]. 实用肝脏病杂志, 2023, 26(2): 193-196.
[6]	刘岗, 张浩, 胡峻. 非酒精性脂肪性肝病患者血清miR-183-5p和miR-96-5p水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 197-201.
[7]	李潇萌, 吴少玉, 王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(2): 202-205.
[8]	张龙玉, 牟丹蕾, 李侗曾, 张佳莹, 梁连春. 粒细胞集落刺激因子治疗重症酒精性肝炎患者疗效的Meta分析^*[J]. 实用肝脏病杂志, 2023, 26(2): 210-213.
[9]	凌佳慧, 倪美鑫, 韩黎黎, 卫栋萍, 戴轶伟, 陈婷婷. 异甘草酸镁治疗自身免疫性肝炎患者血清细胞因子水平变化^*[J]. 实用肝脏病杂志, 2023, 26(2): 214-217.
[10]	李艳芬, 张晓文, 王艳茹, 齐慧芳, 支姗. 应用奥贝胆酸和贝特类药物治疗对熊去氧胆酸治疗不完全应答的原发性胆汁性胆管炎患者临床研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 226-229.
[11]	徐菁, 刘坤, 马竹芳. 异甘草酸镁防治接受化疗的晚期胃癌患者肝肾功能损伤临床研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 234-237.
[12]	程洋, 张峰, 王曦旋, 尹晓春, 肖江强, 张明, 王雷, 邹晓平, 诸葛宇征. 普萘洛尔与卡维地洛预防肝硬化患者并发食管胃静脉曲张破裂出血临床疗效比较^*[J]. 实用肝脏病杂志, 2023, 26(2): 254-257.
[13]	张斌, 赵宇亮, 闫国贝. hUCB-MNCs联合hUC-MSCs静脉输注治疗失代偿期乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 262-265.
[14]	周秋娟, 朱逸明, 马宇航, 陈婷闪. TIPS与PSE术治疗乙型肝炎肝硬化并发脾功能亢进症患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 266-269.
[15]	龚程, 田银生, 刘爽. 不同时间窗手术治疗原发性肝癌自发破裂出血患者2年生存率比较^*[J]. 实用肝脏病杂志, 2023, 26(2): 274-277.